← Back to the Investment Managers Blog

COVID-19 vaccine, U.S. Presidential election and more

Published on 18th August 2020

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

We are pleased to present International Biotechnology Trust’s factsheet for July 2020:


The development of a vaccine for the prevention of the COVID-19 infection is moving forward in the U.S. at impressive speed and the UK government is not far behind under the leadership of the chair of the UK’s Vaccine Taskforce, Kate Bingham, who is also an Investment Manager of the International Biotechnology Trust. Of course, we are extremely proud of Kate and the important work she is doing for the public health of the population of the United Kingdom. For more information please refer to the following link:

Without going into the detailed results of the various vaccines in development, there is growing data to support that one or more vaccine developers will have a vaccine approved in the first half of 2021. The results of the early ongoing vaccine trials are widely documented and information on the latest trial results is readily available to the general public. In my opinion, as an immunologist and medical doctor, I am encouraged by what I see. I am increasingly optimistic about the possibility that the worldwide efforts to develop a vaccine will be successful and faster than we initially anticipated.

The elections in the U.S. are always important for the general equity markets and for the healthcare sector, in particular. This year is no different. In 2016, the Presidential debate focused more on the drug pricing itself, with Hillary Clinton running as candidate for the Democratic Party. This year the Democratic Candidate is Joe Biden, who is considered to have a more "moderate" view on healthcare reform. His message centres on providing the average American with access to affordable healthcare, rather than focusing on drug pricing (for more information, please refer to: https://joebiden.com/healthcare/#). Our view is that this will not have a significant negative impact near term on the healthcare and biotech sectors.

We have seen a strong recovery of the equity markets including the biotech sector after the trough experienced during March 2020. At the end of July 2020, the Nasdaq Biotech Index (NBI in USD) stood at 4,224, a number exceeding the NBI’s peak five years ago on 20 July 2015, at 4,165. The biotech sector is experiencing a strong innovation cycle with an increasing rate of scientific discoveries and a growing number of new pharmaceutical drugs in development. Interest rates are low as part of the monetary policy expansion, following a concerted global effort to respond to the pandemic. However, with many factors at play - the pandemic, US politics, vaccine development, etc, the near-term development could be a bit volatile. In the longer term, we are convinced that this innovative productivity will lead to an increased number of life-saving products which will translate into increased global sales and earnings.


The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).

I do not accept →